Softwr

Research · head to head

Genedata vs Schrodinger

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
Full reviewWebsite
Schrodinger logo

Schrodinger

Research

Physics based molecular modelling and drug discovery software, licensed by token pool

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Schrodinger licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • They diverge on capability: Genedata covers Screener, Schrodinger covers Maestro.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and Schrodinger actually diverge.

Attributes where Genedata and Schrodinger differ
AttributeGenedataSchrodinger
PlatformsWeb, On-premise, Private cloudLinux, macOS, Windows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • Instrument integration
  • GxP-capable deployments

Only in Schrodinger

  • Maestro
  • Glide
  • FEP+
  • Desmond
  • Jaguar
  • LiveDesign
  • Materials Science suite

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Schrodinger
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Schrodinger
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot Schrodinger
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Schrodinger

Schrodinger

  • A medicinal chemistry programme using FEP+ to prioritise which analogues to synthesise, where avoiding a handful of wasted syntheses pays for the licencenot Genedata
  • A structure based design campaign that needs docking at scale against a target with a good crystal structurenot Genedata
  • A materials group modelling polymer or electrolyte properties before committing to formulation experimentsnot Genedata
  • A university modelling group that qualifies for the published academic site licence and needs Maestro across a teaching and research cohortnot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

Schrodinger

  • Licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • Commercial pricing is not published and is negotiated against modules, cores and term, so two companies of similar size can pay very different amounts and neither can benchmark the other.
  • FEP+ needs substantial GPU capacity that is not included in the licence, so the real annual cost includes cloud or on premise hardware that often rivals the software line item.
  • The tools require trained computational chemists to produce trustworthy results, and an organisation without that function will generate predictions it cannot interpret or defend to its own medicinal chemists.
  • Schrodinger runs its own internal drug discovery pipeline alongside selling software to discovery companies, and some prospective customers treat that dual role as a conflict when discussing proprietary targets, which slows procurement even where contractual separation exists.

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

Schrodinger

On request
  • Commercial licence$undefined/year
    • Quoted per customer against modules, cores and licence term
    • Applications draw from a shared token pool that caps concurrency
    • GPU compute for FEP+ and Desmond is a separate cost, on premise or cloud
  • Academic site licence$undefined/year
    • Published academic entry around 7,500 USD a year for a premium package with a token allocation
    • Restricted to academic and research use, not work supporting a commercial enterprise
    • Maestro generally unrestricted with tokens shared for compute heavy applications

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.
Genedata review

Choose Schrodinger if

  • You need maestro.
  • You work on Linux, macOS, Windows, Web.
  • You also want glide.
Schrodinger review

Questions people ask

Is Genedata or Schrodinger better?
Neither clearly leads. Genedata starts at On request and Schrodinger at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or Schrodinger?
Genedata starts at On request and Schrodinger at On request.
Does Genedata or Schrodinger run on more platforms?
Genedata runs on Web, On-premise, Private cloud. Schrodinger runs on Linux, macOS, Windows, Web.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Schrodinger is typically brought in for.
What can Genedata do that Schrodinger cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. Schrodinger covers Maestro, Glide, FEP+, Desmond.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

Schrodinger: How is Schrodinger software licensed?

Annual licences with a shared token pool. Tokens cap how much you can run at once rather than which modules you own outright.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

Schrodinger: Is there published pricing?

Only for academic site licences, which start around 7,500 USD a year for a premium package. Commercial pricing is quoted.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

Schrodinger: Do I need my own GPUs?

For FEP+ and Desmond in practice yes, or cloud GPU capacity. Compute is not included in the licence.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

Schrodinger: Does Schrodinger compete with its customers?

It runs its own drug pipeline as well as selling software. It manages this through contractual separation, but buyers with sensitive targets should raise it during procurement.

Share

Related pages

More on Genedata

More on Schrodinger

Keep looking

Other head to heads